Study on the effects of supplements containing lutein on spontaneous resolution in eyes with chronic central serous chorioretinopathy

Study on the effects of supplements containing lutein on spontaneous resolution in eyes with chronic central serous chorioretinopathy - Study on the effects of supplements containing lutein on chronic central serous chorioretinopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005372

Enrollment

100

Registered

2011-04-16

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic central serous chorioretinopathy

Interventions

multivitamins, minerals, and luten placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. serous retinal detachment detectable on optical coherence tomography (OCT) with diagnosis of central serous chorioretinopathy (CSC) on the basis of fluorescein angiography 2. chronic CSC with a + any of b, c, d a. not diagnosed as polypoidal choroidal vasculopathy (PCV) on fluorescein angigraphy b. visual acuity loss due to persistent serous retinal detachment c. durations of symptoms over 3 months d. hyperautofluorescence in the area with serous retinal detachment 3. age over 40 years, obtainable for informed consent 4. Japanese patients 5. patients considered as eligible for study by the investigator

Exclusion criteria

Exclusion criteria: 1. presence of hard exudate or subretinal hemorrhage in or around serous retinal detachment 2. past history of photocoagulation or photodynamic therapy 3. presence of other macular diseases 4. presence of uveitis 5. myopia with -8D or higher 6. past history of vitrectomy 7. hazy media causing difficulties in fundus examinations 8. active exudative age-related macular degeneration in a fellow eye 9. allergic to lutein, anti-oxidants, and minerals 10. daily take of lutein, anti-oxidants, or other supplements 11. pregnant or planned for pregnancy 12. undergone intraocular surgeries within the previous 6 months 13. judged by the investigator to be ineligible for other reasons

Design outcomes

Primary

Measure	Time frame
(1) Rate of spontaneous resolution of central serous chorioretinopathy (2) Changes in macular volume measured by optical coherence tomography	—

Secondary

Measure	Time frame
Best-corrected visual acuity	—

Countries

Japan

Contacts

Public ContactTsutomu Yasukawa

Nagoya City University Graduate School of Medical Sciences Department of Ophthalmology and Visual Science

yasukawa@med.nagoya-cu.ac.jp052-853-8251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026